コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 lly relevant model of mucosal infection with herpes simplex virus type 2.
2 l among 3408 persons coinfected with HIV and herpes simplex virus type 2.
3 nd spinal cord in response to infection with herpes simplex virus type 2.
4 intravaginal challenge with 4.0 log10 pfu of herpes simplex virus type 2.
5 mydia trachomatis, Neisseria gonorrhoeae, or herpes simplex virus type 2.
6 infected with HIV-1 are dually infected with herpes simplex virus type 2.
7 t assay for immunoglobulin (IgG) antibody to herpes simplex virus type 2.
8 8 cytotoxic T lymphocyte clones specific for herpes simplex virus type 2, a pathogen with a complex g
9 us and adenovirus only weakly stimulated and herpes simplex virus type 2 and bacteria did not stimula
10 osexual people who were dually infected with herpes simplex virus type 2 and HIV-1 were randomly assi
11 nal IgG seropositivity or antibody levels to herpes simplex virus type 2 and risk of schizophrenia.
12 lts who were seropositive for both HIV-1 and herpes simplex virus type 2, and their HIV-1 seronegativ
13 testing for human immunodeficiency virus and herpes simplex virus type 2, and were screened for Neiss
14 gG and IgM immunoglobulins and antibodies to herpes simplex virus type 2 are at increased risk for th
15 against cervical cancer, cervical dysplasia, herpes simplex virus type 2, chlamydia, and syphilis.
16 HIV shedding in 67 women with HIV type 1 and herpes simplex virus type 2 coinfection, during 2 menstr
17 load, viral set point, CD4(+) T-cell count, herpes simplex virus type 2 detection, and gonorrhea.
18 ubjects in Uganda were tested by HerpeSelect herpes simplex virus type 2 enzyme-linked immunosorbent
19 ce of a thymidine kinase-deficient strain of herpes simplex virus type 2 from the female genital trac
20 virtually the entire extracellular domain of herpes simplex virus type 2 gB, was digested with trypsi
21 ZV gE were fused to amino acids 30 to 545 of herpes simplex virus type 2 gE did not show an increased
22 eno-associated virus (AAV) vector expressing herpes simplex virus type 2 glycoprotein B led to the ge
23 mmunogenicity, and efficacy of a recombinant herpes simplex virus type 2 glycoprotein D and B vaccine
24 -acid residue truncated, recombinant form of herpes simplex virus type 2 glycoprotein gB (HSV gB2t) p
25 t association between maternal antibodies to herpes simplex virus type 2 glycoprotein gG2 and subsequ
26 ntly higher in those who became positive for herpes simplex virus type 2 (HSV-2) (men: OR, 5.60; wome
27 ncy virus (HIV) agent that decreased risk of herpes simplex virus type 2 (HSV-2) acquisition in HIV p
28 duces human immunodeficiency virus (HIV) and herpes simplex virus type 2 (HSV-2) acquisition, and HSV
29 ated the relationship between condom use and herpes simplex virus type 2 (HSV-2) and HSV type 1 (HSV-
30 ies consistently demonstrate synergy between herpes simplex virus type 2 (HSV-2) and human immunodefi
33 y of male circumcision for the prevention of herpes simplex virus type 2 (HSV-2) and human papillomav
35 fumarate (TDF) has in vitro activity against herpes simplex virus type 2 (HSV-2) and reduced HSV-2 ac
36 ies were used to determine the prevalence of herpes simplex virus type 2 (HSV-2) antibodies by using
38 an immunodeficiency virus type 1 (HIV-1) and herpes simplex virus type 2 (HSV-2) are responsible for
41 tential of conferring protective immunity to herpes simplex virus type 2 (HSV-2) by selectively induc
44 ative strategies for controlling the growing herpes simplex virus type 2 (HSV-2) epidemic are needed.
49 In addition to eleven glycoproteins, the herpes simplex virus type 2 (HSV-2) genome encodes sever
51 nt clinical trials, a vaccine that contained herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2)
53 ted two double-blind, randomized trials of a herpes simplex virus type 2 (HSV-2) glycoprotein-D-subun
54 ndoms for protection against transmission of herpes simplex virus type 2 (HSV-2) has been examined in
56 lovir reduces risk of sexual transmission of herpes simplex virus type 2 (HSV-2) in HSV-2-serodiscord
58 ressing full-length glycoprotein D (gD) from herpes simplex virus type 2 (HSV-2) in mice and guinea p
60 Intravaginal (IVAG) inoculation of wild-type herpes simplex virus type 2 (HSV-2) in mice causes epith
64 investigation evaluated immunity to vaginal herpes simplex virus type 2 (HSV-2) infection after loca
65 tle is known about risk factors for incident herpes simplex virus type 2 (HSV-2) infection among men
66 CXCL10(-/-)) mice which succumbed to genital herpes simplex virus type 2 (HSV-2) infection and posses
68 ative to host immune defense against genital herpes simplex virus type 2 (HSV-2) infection have been
70 gated the mechanism of resistance to genital herpes simplex virus type 2 (HSV-2) infection in mice tr
71 xamination Survey (1988-1994), prevalence of herpes simplex virus type 2 (HSV-2) infection in the Uni
78 stimate the impact of prevalent and incident herpes simplex virus type 2 (HSV-2) infection on the acq
79 mmune system's protective effect against one herpes simplex virus type 2 (HSV-2) infection protects a
81 ical and virologic manifestations of genital herpes simplex virus type 2 (HSV-2) infection vary widel
88 tic T cells play a major role in controlling herpes simplex virus type 2 (HSV-2) infections in humans
89 from 29 patients with first-episode genital herpes simplex virus type 2 (HSV-2) infections were test
92 to test the activity of microbicides against herpes simplex virus type 2 (HSV-2) introduced in semina
104 studies using viral cultures rarely reported herpes simplex virus type 2 (HSV-2) isolation from the m
117 cyclovir, infection with acyclovir-resistant herpes simplex virus type 2 (HSV-2) remains uncommon.
119 ulation of mice with an attenuated strain of herpes simplex virus type 2 (HSV-2) resulted in vigorous
120 Lastly, we detected rare (1 virus/100 cells) Herpes simplex virus type 2 (HSV-2) sequences in a tissu
121 eficiency virus (HIV) infection and possible herpes simplex virus type 2 (HSV-2) shedding and genital
128 mmunodeficiency virus (HIV) acquisition with herpes simplex virus type 2 (HSV-2) was assessed among m
129 fected with human immunodeficiency virus and herpes simplex virus type 2 (HSV-2) was conducted to ass
130 ages 14-19 years had an STD: chlamydia, 27%; herpes simplex virus type 2 (HSV-2), 14%; gonorrhea, 6%;
131 , when infected intravaginally with virulent herpes simplex virus type 2 (HSV-2), developed more seve
132 iological data included laboratory diagnosed herpes simplex virus type 2 (HSV-2), syphilis, chlamydia
133 virus type 1 (HIV-1) are also infected with herpes simplex virus type 2 (HSV-2), which is frequently
134 and longitudinal plasma HIV-1 loads between herpes simplex virus type 2 (HSV-2)-seropositive and -se
135 mg) for the prevention of HIV acquisition in herpes simplex virus type 2 (HSV-2)-seropositive persons
136 rkers in Harare, Zimbabwe, were screened for herpes simplex virus type 2 (HSV-2)-specific antibodies,
138 Meridian Diagnostics have recently designed herpes simplex virus type 2 (HSV-2)-specific enzyme immu
147 immunodeficiency virus (HIV), syphilis, and herpes simplex virus type 2 (HSV-2); and were seen over
149 administration of influenza hemagglutinin or herpes simplex virus type-2 (HSV-2) glycoprotein D with
150 cked this process by fusing a model antigen, herpes simplex virus type-2 (HSV-2) glycoprotein gD, to
152 he impact of antiretroviral therapy (ART) on herpes simplex virus type-2 (HSV-2) replication is uncle
155 he association between DMPA use and incident herpes simplex virus type 2 (HSV2) infection in women.
156 MC) reduces heterosexual acquisition of HIV, herpes simplex virus type 2, human papillomavirus (HPV),
159 that MDMA causes increased susceptibility to herpes simplex virus type 2 infection in mice and earlie
162 ter or activator sequences downstream of the herpes simplex virus type 2 latency-associated transcrip
164 st to a lesion from a patient with recurrent herpes simplex virus type 2, no message for IL-4 could b
170 in those with prevalent infection, and with herpes simplex virus type 2 seropositivity in subjects w
171 rtner-associated risk for HIV infection, and herpes simplex virus type 2 seropositivity were also pre
172 HIV-1 RNA of the HIV-1-infected partner and herpes simplex virus type 2 serostatus and age of the HI
173 for subsequent circumcision status, baseline herpes simplex virus type 2 serostatus, and sexual and s
175 etween plasma and serum for the detection of herpes simplex virus type 2-specific immunoglobulin G an
176 ded controls for sociodemographic variables, herpes simplex virus type-2 status, and recreational dru
178 wever, we noted no protective effect against herpes simplex virus type 2, syphilis, or gonorrhoea.
179 responses to the prevalent chronic pathogen, herpes simplex virus type 2, that cross-react with cells
180 susceptible to challenge with a low dose of herpes simplex virus type 2; the response of PRO 2000-tr
181 performed to determine whether adaptation of herpes simplex virus type 2 to replication in cultured c
182 Personal interviews, tests for antibodies to herpes simplex virus type 2, Treponema pallidum, and hep
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。